A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer.
Future Oncol
; 20(14): 951-958, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38018441
ABSTRACT
Purpose:
To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy.Methods:
This study included 156 patients with primary breast cancer 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG-rituximab and combined method in the detected lymph nodes.Results:
According to the verification test, the imaging rate of ICG-rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001).Conclusion:
For ICG-rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 µg/rituximab 375 µg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Ganglio Linfático Centinela
Límite:
Female
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article